Predictive Role of Neostromal CD10 Expression in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy

Overview

Journal Pathol Oncol Res

Specialty Oncology

Date 2023 Jan 23

PMID 36685105

Authors

Orsolya Olah

Edit Majlat

Renata Koszo

Zoltan Vereb

Andras Voros

Affiliations

Soon will be listed here.

Abstract

The therapeutic strategy of invasive breast cancer is based on routine histopathological markers (estrogen-, progesterone receptor, HER2, Ki67) routinely evaluated in tumor cells. However, the assessment of cancer stroma could influence therapeutic strategies. Studies have shown that stromal expression of CD10, a zinc-dependent metalloproteinase, is associated with biological aggressiveness of the tumor. In the present retrospective study, we aimed to evaluate stromal CD10 expression and association between CD10 expression and response to neoadjuvant chemotherapy in invasive breast cancer. CD10 immunohistochemistry was performed on core biopsies taken before the neoadjuvant therapy. Stromal CD10 expression was determined and compared with well-known predictive and prognostic tissue markers as well as with the following groups defined according to the degree of tumor response: no regression, partial regression, and complete regression. A total of 60 locally advanced invasive breast carcinomas of "no special type" were included. The proportion of CD10 positive tumors was significantly higher in the "no regression" group compared to "complete regression" group ( = 0.000). Stromal CD10 expression was found to be significantly associated with decrease in response to neoadjuvant chemotherapy. According to CD10 expression we did not find any difference in hormone receptor status, Ki67, tumor grade or neostromal area. Our data suggest that CD10 expression can serve as a predictive marker of the effect of neoadjuvant chemotherapy in breast cancer patients. Therefore, its inclusion into the routine assessment of biopsies to tailor tumor-specific therapeutic strategies merits consideration.

References

Voutsadakis I, Vlachostergios P, Daliani D, Karasavvidou F, Kakkas G, Moutzouris G . CD10 is inversely associated with nuclear factor-kappa B and predicts biochemical recurrence after radical prostatectomy. Urol Int. 2012; 88(2):158-64. DOI: 10.1159/000335299. View

Goodman Jr O, Febbraio M, Simantov R, Zheng R, Shen R, Silverstein R . Neprilysin inhibits angiogenesis via proteolysis of fibroblast growth factor-2. J Biol Chem. 2006; 281(44):33597-605. DOI: 10.1074/jbc.M602490200. View

Allison K, Hammond M, Dowsett M, McKernin S, Carey L, Fitzgibbons P . Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. J Clin Oncol. 2020; 38(12):1346-1366. DOI: 10.1200/JCO.19.02309. View

Wolff A, Hammond M, Allison K, Harvey B, Mangu P, Bartlett J . Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol. 2018; 36(20):2105-2122. DOI: 10.1200/JCO.2018.77.8738. View

Orimo A, Weinberg R . Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle. 2006; 5(15):1597-601. DOI: 10.4161/cc.5.15.3112. View

Sato Y, Itoh F, Hinoda Y, Ohe Y, Nakagawa N, Ueda R . Expression of CD10/neutral endopeptidase in normal and malignant tissues of the human stomach and colon. J Gastroenterol. 1996; 31(1):12-7. DOI: 10.1007/BF01211181. View

Jana S, Jha B, Patel C, Jana D, Agarwal A . CD10-a new prognostic stromal marker in breast carcinoma, its utility, limitations and role in breast cancer pathogenesis. Indian J Pathol Microbiol. 2014; 57(4):530-6. DOI: 10.4103/0377-4929.142639. View

Thomas S, Babu R, Agarwal K, Puri V, Jain M, Andley M . Effect of neoadjuvant chemotherapy on stromal CD10 antigens in breast cancer - a preliminary study. Indian J Cancer. 2013; 50(1):46-51. DOI: 10.4103/0019-509X.112299. View

Dhande A, Khandeparkar S, Joshi A, Kulkarni M, Pandya N, Mohanapure N . Stromal expression of CD10 in breast carcinoma and its correlation with clinicopathological parameters. South Asian J Cancer. 2019; 8(1):18-21. PMC: 6348787. DOI: 10.4103/sajc.sajc_56_18. View

10.

Pollard J . Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004; 4(1):71-8. DOI: 10.1038/nrc1256. View

11.

Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G . The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2014; 26(2):259-71. PMC: 6267863. DOI: 10.1093/annonc/mdu450. View

12.

Lin E, Pollard J . Macrophages: modulators of breast cancer progression. Novartis Found Symp. 2004; 256:158-68. View

13.

Vo T, Mekata E, Umeda T, Abe H, Kawai Y, Mori T . Prognostic impact of CD10 expression in clinical outcome of invasive breast carcinoma. Breast Cancer. 2013; 22(2):117-28. DOI: 10.1007/s12282-013-0459-1. View

14.

Jinga D, Blidaru A, Condrea I, Ardeleanu C, Dragomir C, Szegli G . MMP-9 and MMP-2 gelatinases and TIMP-1 and TIMP-2 inhibitors in breast cancer: correlations with prognostic factors. J Cell Mol Med. 2006; 10(2):499-510. PMC: 3933137. DOI: 10.1111/j.1582-4934.2006.tb00415.x. View

15.

Cserni G, Kulka J, Francz M, Jaray B, Kalman E, Kovacs I . [Pathological diagnosis, work-up and reporting of breast cancer. Recommendations of the 3rd Hungarian Consensus Conference on Breast Cancer]. Magy Onkol. 2016; 60(3):209-28. View

16.

Curran C, Keely P . Breast tumor and stromal cell responses to TGF-β and hypoxia in matrix deposition. Matrix Biol. 2012; 32(2):95-105. PMC: 3615133. DOI: 10.1016/j.matbio.2012.11.016. View

17.

Smollich M, Gotte M, Yip G, Yong E, Kersting C, Fischgrabe J . On the role of endothelin-converting enzyme-1 (ECE-1) and neprilysin in human breast cancer. Breast Cancer Res Treat. 2007; 106(3):361-9. DOI: 10.1007/s10549-007-9516-9. View

18.

Puri V, Jain M, Mahajan G, Pujani M . Critical appraisal of stromal CD10 staining in fibroepithelial lesions of breast with a special emphasis on expression patterns and correlation with WHO grading. J Cancer Res Ther. 2016; 12(2):667-70. DOI: 10.4103/0973-1482.177215. View

19.

Shipp M, Look A . Hematopoietic differentiation antigens that are membrane-associated enzymes: cutting is the key!. Blood. 1993; 82(4):1052-70. View

20.

Su S, Chen J, Yao H, Liu J, Yu S, Lao L . CD10GPR77 Cancer-Associated Fibroblasts Promote Cancer Formation and Chemoresistance by Sustaining Cancer Stemness. Cell. 2018; 172(4):841-856.e16. DOI: 10.1016/j.cell.2018.01.009. View